spec sheet11 rows
Renzapride is a bicyclic benzamide that acts as a full 5-HT4 receptor agonist and simultaneously as a 5-HT3 receptor antagonist, a dual mechanism that made it an unusual candidate for irritable bowel syndrome. It accelerates gastrointestinal transit through 5-HT4 agonism while its 5-HT3 antagonism was intended to modulate visceral sensitivity, and it was developed principally for constipation-predominant irritable bowel syndrome. Radioligand studies confirm high affinity for 5-HT3 and 5-HT4 receptors, with only minor metabolites and little cytochrome P450 inhibition. Renzapride reached late-stage trials but was not approved.
- Dual 5-HT4 agonist and 5-HT3 antagonist in one molecule
- Full 5-HT4 agonism accelerates gastrointestinal transit
- 5-HT3 antagonism aimed at reducing visceral pain
- High and selective serotonergic receptor affinity
- Largely inactive primary metabolite
- Low cytochrome P450 inhibition and drug-interaction risk
- Class association with ischemic colitis
- Vascular caution applied to serotonergic gut agents
- Diarrhea and abdominal cramping from prokinetic action
Overview
Renzapride is distinctive among 5-HT4 agonists for its deliberate dual pharmacology, combining full 5-HT4 receptor agonism with 5-HT3 receptor antagonism in a single molecule, a design intended to both accelerate transit and blunt visceral hypersensitivity in irritable bowel syndrome [1].
Detailed radioligand binding work characterized renzapride as selective for serotonergic receptors, with high affinity for human 5-HT3 and guinea-pig 5-HT4 receptors and additional inhibitory activity at 5-HT2B receptors; its primary metabolite, renzapride N-oxide, had much lower affinity, and renzapride did not meaningfully inhibit the major cytochrome P450 drug-metabolizing enzymes, implying limited metabolic drug-interaction potential [1]. This profile positioned it as a potent, generally full 5-HT4 agonist and 5-HT3 antagonist with a clean metabolic footprint.
Renzapride advanced into clinical development for constipation-predominant irritable bowel syndrome, but like other serotonergic irritable bowel therapies it drew scrutiny over vascular safety; it was among the 5-HT4 agonists associated with ischemic colitis in the postmarketing and pharmacovigilance literature [2]. Broader European safety reviews of irritable bowel syndrome pharmacotherapy situated renzapride within a class whose benefits and risks required careful post-marketing characterization [3]. It ultimately did not achieve regulatory approval.
- Renzapride is unusual in being a full 5-HT4 agonist and a 5-HT3 antagonist at once, a combination meant to speed the gut while simultaneously calming visceral pain signalling.
- Its main metabolite, renzapride N-oxide, is largely inactive, and renzapride barely inhibits cytochrome P450 enzymes, giving it a notably clean drug-interaction profile.
Mechanism
Renzapride engages two receptor systems with opposite functional consequences that are complementary in the gut. As a full 5-HT4 receptor it enhances release from myenteric neurons, stimulating the peristaltic reflex and accelerating gastric, small-bowel, and colonic transit. As a 5-HT3 receptor it dampens serotonergic signalling on visceral afferents, an action intended to reduce the abdominal pain and hypersensitivity of irritable bowel syndrome. It also shows inhibitory activity at 5-HT2B receptors, and because it is only minimally metabolized and does not strongly inhibit major cytochrome P450 enzymes, its metabolites contribute little to its overall profile.
receptor fingerprint
5-HT4 receptorFull agonist enhancing acetylcholine release
5-HT3 receptorAntagonist on visceral afferents
5-HT2B receptorInhibitory activity
Cytochrome P450 enzymesMinimal inhibition; limited metabolism
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
The principal safety concern that shadowed renzapride is the class association between serotonergic irritable bowel therapies and ischemic colitis, alongside the general vascular caution applied to 5-HT4 agonists after the tegaserod experience. Its favourable metabolic profile, with limited cytochrome P450 inhibition and low-affinity metabolites, reduces the risk of pharmacokinetic drug interactions. Typical gastrointestinal effects such as diarrhea and abdominal cramping accompany its prokinetic action. Comprehensive long-term safety was never fully established because it did not reach the market.
History
Renzapride originated from Beecham research as BRL-24924 and was later developed clinically under the code ATL-1251 by Alizyme for irritable bowel syndrome, particularly the constipation-predominant subtype. Its dual 5-HT4 agonist and 5-HT3 antagonist mechanism attracted interest as a potentially more complete approach to irritable bowel symptoms. Despite progressing into late-stage trials in the 2000s, it did not demonstrate a sufficiently compelling benefit-risk profile to gain approval and development was ultimately discontinued.
Reputation
Renzapride is regarded as a pharmacologically interesting dual-mechanism serotonergic agent whose combined 5-HT4 agonism and 5-HT3 antagonism made it a notable, if ultimately unsuccessful, irritable bowel syndrome candidate. It is frequently cited in reviews of serotonergic gut pharmacology as an example of rational polypharmacology within a single molecule. It has no nootropic profile and is remembered primarily as an investigational gastrointestinal drug.
Subjective profileweighing the evidence above
Dead in development, and reasonably so. The dual 5-HT4 agonist and 5-HT3 antagonist design was clever for irritable bowel, but it never cleared approval and it sits under the ischemic colitis shadow that follows serotonergic gut drugs. Nothing to seek out.
Resources
This entry is here for reference.
Research
- 2006first citedSystematic review: the safety and tolerability of pharmacological agents for treatment of irrit…
- 2011most recentThe risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic th…
- 1.Pharmacology and metabolism of renzapride: a novel therapeutic agent for the potential treatment of irritable bowel syndrome
- 2.The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies
- 3.Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome, a European perspective
3 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
What makes renzapride unusual?
It is simultaneously a full 5-HT4 receptor agonist and a 5-HT3 receptor antagonist, combining transit acceleration with intended reduction of visceral pain in a single molecule.
What was it developed for?
Primarily constipation-predominant irritable bowel syndrome, where its dual mechanism was expected to address both motility and sensitivity.
Was it approved?
No. Renzapride progressed into late-stage trials but did not achieve a sufficiently favourable benefit-risk profile and was not marketed.
Does it interact with other drugs?
Its profile suggests low risk, since it is minimally metabolized and does not strongly inhibit the major cytochrome P450 enzymes.
Is it a cognitive enhancer?
No. Renzapride is a peripheral gastrointestinal agent and has not been studied for cognition.
Limitations of the evidence
- Never approved, so long-term safety unestablished
Adverse effects
- Class association with ischemic colitis
- Vascular caution applied to serotonergic gut agents
- Diarrhea and abdominal cramping from prokinetic action